Indalo Therapeutics
4320 Forest Park Avenue
Suite 304
St. Louis
Missouri
63108
United States
Tel: 314-932-4032 X317
Website: https://indalotherapeutics.com/
About Indalo Therapeutics
Indalo Therapeutics is a preclinical-stage biotechnology company dedicated to improving the lives of patients suffering from debilitating fibrotic diseases. Founded on groundbreaking scientific discoveries and leveraging cutting-edge insight into the molecular drivers of aberrant scarring, Indalo is harnessing the collective experience of a seasoned team of pharmaceutical scientists and executives to tackle some of the most urgent unmet medical needs in the fibrosis space.
YEAR FOUNDED:
October 2016
LEADERSHIP:
Founder and CMO: Williamson Z. Bradford, M.D., Ph.D.
Founder and CSO: Scott D. Seiwert, Ph.D.
Sr. VP of Pharmaceutical Development: Ramachandran Radhakrishnan, Ph.D.
Sr. VP of Translational Science: Karl Kossen, Ph.D.
VP and Head of Business Operations: George H. Capps, M.S., M.B.A.
12 articles about Indalo Therapeutics
-
Indalo Therapeutics Appoints Healthcare Industry Veteran and Serial Entrepreneur Michael Heffernan as Board Chair
12/17/2019
Mr. Heffernan was most recently CEO of Collegium Pharmaceutical, a publicly traded pharmaceutical company that he founded and that is focused on developing and commercializing products for the treatment of chronic pain and related disorders.
-
Indalo Therapeutics Presents Phase 1 Clinical Trial Results for Lead Antifibrotic Drug Candidate IDL-2965
11/11/2019
Demonstrates strong safety and oral PK
-
Indalo Therapeutics Initiates Dosing in IPF Patients with Lead Antifibrotic Drug Candidate IDL-2965
10/21/2019
Indalo Therapeutics, a biopharmaceutical company discovering and developing integrin antagonists for patients suffering from serious fibrotic diseases such as idiopathic pulmonary fibrosis (IPF) and nonalcoholic steatohepatitis (NASH), today announced that the first IPF patient has been dosed in a clinical trial of the company's lead drug candidate IDL-2965.
-
Indalo Therapeutics Initiates Dosing in Phase 1 Clinical Trial of Lead Antifibrotic Drug Candidate IDL-2965
4/18/2019
Indalo Therapeutics, a biopharmaceutical company discovering and developing integrin antagonists for patients suffering from serious fibrotic diseases such as nonalcoholic steatohepatitis (NASH) and idiopathic pulmonary fibrosis (IPF), today announced the first healthy volunteer has been dosed in a Phase 1 clinical trial of the company's lead drug candidate IDL-2965.
-
St. Louis, Missouri is one of the fastest-growing and top-ranked emerging life sciences markets in the U.S., ranking sixth in a recent CBRE Research report.
-
BioSpace Movers and Shakers: Feb. 1
2/1/2019
As January ends, biotech and pharma companies tap new leaders to help drive strategic visions. New hires at Histogen, Indalo, Novartis Oncology, Calico, and more. -
Robert Jacks, co-founder and former chief financial officer of Symbiomix Therapeutics, has taken over the reins of Cambridge, Mass.-based Indalo Therapeutics and will help guide the company in the development of therapies for patients suffering from serious fibrotic diseases such as NASH and idio...
-
Indalo Therapeutics Appoints Seasoned Biopharmaceutical Executive Robert Jacks President & CEO
1/28/2019
Indalo Therapeutics, a biopharmaceutical company discovering and developing integrin antagonists for patients suffering from serious fibrotic diseases such as nonalcoholic steatohepatitis (NASH) and idiopathic pulmonary fibrosis (IPF), today announced that Robert Jacks has been appointed President & CEO.
-
Indalo Therapeutics is based in St. Louis and was formed in October 2016 from the merger of Antegrin Therapeutics and Cascadia Therapeutics.
-
BioSpace is proud to present its NextGen "Class of 2018," a list of 20 up-and-coming life science companies in North America that started up no earlier than 2015.
-
Indalo Therapeutics Formed by Merger of Antegrin and Cascadia
10/17/2017
Financial terms of the deal were not disclosed.
-
Biotech Startup Indalo Therapeutics Nabs $9M
8/4/2017